fluoxetine has been researched along with Alcoholism in 51 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Alcoholism: A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The drugs relieve depressive disorders: fluvoxamine by the 7th day of treatment, sertraline, paroxetine, citalopram by the 14th day, fluoxetine by the 30th day of therapy." | 9.41 | [Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study]. ( Komarov, SD; Severtsev, VV; Vdovin, AS; Vinnikova, MA, 2021) |
| " In addition, hypericum extracts, as well as standard antidepressants such as the tricyclic, impramine, and the selective serotonin reuptake inhibitor, fluoxetine, have been reported to be of therapeutic benefit in the treatment of alcoholism, as these compounds may reduce alcohol craving and/or intake in particular subgroups of patients." | 7.70 | Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism. ( de Beun, R; De Vry, J; Jentzsch, KR; Maurel, S; Schreiber, R, 1999) |
| "The drugs relieve depressive disorders: fluvoxamine by the 7th day of treatment, sertraline, paroxetine, citalopram by the 14th day, fluoxetine by the 30th day of therapy." | 5.41 | [Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study]. ( Komarov, SD; Severtsev, VV; Vdovin, AS; Vinnikova, MA, 2021) |
| "The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics." | 5.08 | Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics. ( Black, A; Cornelius, JR; Cornelius, MD; Ehler, JG; Jarrett, PJ; Levin, RL; Mann, JJ; Perel, JM; Salloum, IM, 1995) |
| " In this study, 25 smokers with DSM-III-R diagnoses of both major depressive disorder and alcohol dependence were randomized to fluoxetine or placebo in a 12-week, double-blind, parallel group trial." | 5.08 | Double-blind fluoxetine in depressed alcoholic smokers. ( Black, A; Cornelius, JR; Cornelius, MD; Ehler, JG; Jarrett, PJ; Perel, JM; Salloum, IM; Thase, ME, 1997) |
| "The selective serotonergic medication fluoxetine has demonstrated efficacy in the treatment of major depression and has suggested efficacy in the treatment of alcoholism." | 5.08 | Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. ( Black, A; Cornelius, JR; Cornelius, MD; Ehler, JG; Jarrett, PJ; Perel, JM; Salloum, IM; Thase, ME, 1997) |
| " In this study, 17 patients with DSM-III-R diagnoses of major depressive disorder, alcohol dependence, and cocaine abuse were included along with 34 non-cocaine-abusing depressed alcoholics in a pharmacotherapy trial involving the SSRI antidepressant fluoxetine." | 5.08 | Fluoxetine versus placebo in depressed alcoholic cocaine abusers. ( Cornelius, JR; Daley, DC; Haskett, RF; Jones-Barlock, A; Perel, JM; Salloum, IM; Thase, ME; Upsher, C, 1998) |
| "The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has suggested efficacy in the treatment of alcoholism." | 5.07 | Fluoxetine trial in suicidal depressed alcoholics. ( Cornelius, JR; Cornelius, MD; Ehler, JG; Mann, JJ; Perel, JM; Salloum, IM; Thase, ME, 1993) |
| "The effects of fluoxetine, a relatively selective long-acting serotonin uptake inhibitor, on the consumption of alcoholic and nonalcoholic drinks, cigarette smoking, and body weight were assessed in 29 men who were early stage problem drinkers." | 5.06 | Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. ( Kadlec, KE; Naranjo, CA; Sanhueza, P; Sellers, EM; Woodley-Remus, D, 1990) |
| " In addition, hypericum extracts, as well as standard antidepressants such as the tricyclic, impramine, and the selective serotonin reuptake inhibitor, fluoxetine, have been reported to be of therapeutic benefit in the treatment of alcoholism, as these compounds may reduce alcohol craving and/or intake in particular subgroups of patients." | 3.70 | Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism. ( de Beun, R; De Vry, J; Jentzsch, KR; Maurel, S; Schreiber, R, 1999) |
| "Naltrexone (NTX) and fluoxetine (FLU) are useful for treating alcoholism and depression, respectively." | 3.69 | Combination of naltrexone and fluoxetine on rats' propensity to take alcoholic beverage. ( Cavallaro, CA; Chattophadyay, S; Gardell, LR; Hubbell, CL; Reid, LD; Whalen, CA, 1997) |
| "Fluoxetine-treated subjects who remained sober at 12 weeks reported a significant decrease in mean subjective alcohol craving scores from 2." | 2.68 | A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. ( Kabel, DI; Petty, F, 1996) |
| "bromocriptine)." | 2.39 | Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. ( Anton, RF, 1996) |
| "Our study included 101 patients with major depressive disorder and alcohol use disorder (average age: 41." | 1.62 | Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders. ( Bryun, EA; Grishina, EA; Pankratenko, EP; Petukhov, AE; Ryzhikova, KA; Shipitsyn, VV; Skryabin, VY; Sychev, DA; Torrado, MV; Zastrozhin, MS, 2021) |
| "fluoxetine treatment induced a long-lasting increase in alcohol consumption during relapse, an effect that was not observed in the case of bupropion treatment." | 1.51 | Bupropion, a possible antidepressant without negative effects on alcohol relapse. ( Alen, F; Antón, M; Arco, R; Ballesta, A; de Fonseca, FR; de Heras, RG; Nogueira-Arjona, R; Orio, L; Pavón, FJ; Ramírez-López, M; Romero-Sanchiz, P; Serrano, A; Suárez, J; Vargas, A, 2019) |
| "Aripiprazole (ARI) is an atypical antipsychotic drug, which has also been shown to have a beneficial effect on cognitive function." | 1.40 | Evaluation of antidepressant and memory-improving efficacy of aripiprazole and fluoxetine in alcohol-preferring rats. ( Burda-Malarz, K; Czubak, A; Jędrzejewski, L; Kus, K; Nowakowska, E; Ratajczak, P; Sadowski, C, 2014) |
| "Milnacipran was also tested for relapse after protracted abstinence and on ethanol-induced (1." | 1.37 | Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats. ( Alaux-Cantin, S; André, E; Houchi, H; Legastelois, R; Naassila, M; Pierrefiche, O; Simon O'Brien, E; Vilpoux, C, 2011) |
| "Buspirone was without important effects on the high alcohol preferring rats." | 1.29 | Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. ( Meert, TF, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.96) | 18.7374 |
| 1990's | 29 (56.86) | 18.2507 |
| 2000's | 10 (19.61) | 29.6817 |
| 2010's | 8 (15.69) | 24.3611 |
| 2020's | 3 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Zastrozhin, MS | 1 |
| Skryabin, VY | 1 |
| Petukhov, AE | 1 |
| Pankratenko, EP | 1 |
| Grishina, EA | 1 |
| Ryzhikova, KA | 1 |
| Torrado, MV | 1 |
| Shipitsyn, VV | 1 |
| Bryun, EA | 1 |
| Sychev, DA | 1 |
| Vinnikova, MA | 1 |
| Severtsev, VV | 1 |
| Komarov, SD | 1 |
| Vdovin, AS | 1 |
| Ballesta, A | 2 |
| Orio, L | 1 |
| Arco, R | 2 |
| Vargas, A | 1 |
| Romero-Sanchiz, P | 1 |
| Nogueira-Arjona, R | 1 |
| de Heras, RG | 1 |
| Antón, M | 1 |
| Ramírez-López, M | 1 |
| Serrano, A | 1 |
| Pavón, FJ | 1 |
| de Fonseca, FR | 1 |
| Suárez, J | 2 |
| Alen, F | 2 |
| Khom, S | 1 |
| Natividad, LA | 1 |
| Varodayan, FP | 1 |
| Patel, RR | 1 |
| Kirson, D | 1 |
| Bajo, M | 1 |
| Rubio, L | 1 |
| Martin-Fardon, R | 1 |
| Rodríguez de Fonseca, F | 1 |
| Roberto, M | 1 |
| Burda-Malarz, K | 2 |
| Kus, K | 2 |
| Ratajczak, P | 2 |
| Czubak, A | 2 |
| Hardyk, S | 1 |
| Nowakowska, E | 2 |
| Jędrzejewski, L | 1 |
| Sadowski, C | 1 |
| Aragones, JM | 1 |
| Blanch, CE | 1 |
| Guillen-Font, A | 1 |
| Escote-Llobet, S | 1 |
| Hu, J | 1 |
| Xia, Y | 1 |
| Wu, Z | 1 |
| Liu, L | 1 |
| Tang, C | 1 |
| George, DT | 1 |
| Phillips, MJ | 1 |
| Lifshitz, M | 1 |
| Lionetti, TA | 1 |
| Spero, DE | 1 |
| Ghassemzedeh, N | 1 |
| Doty, L | 1 |
| Umhau, JC | 1 |
| Rawlings, RR | 1 |
| Simon O'Brien, E | 1 |
| Legastelois, R | 1 |
| Houchi, H | 1 |
| Vilpoux, C | 1 |
| Alaux-Cantin, S | 1 |
| Pierrefiche, O | 1 |
| André, E | 1 |
| Naassila, M | 1 |
| Hirschtritt, ME | 1 |
| Pagano, ME | 1 |
| Christian, KM | 1 |
| McNamara, NK | 1 |
| Stansbrey, RJ | 1 |
| Lingler, J | 1 |
| Faber, JE | 1 |
| Demeter, CA | 1 |
| Bedoya, D | 1 |
| Findling, RL | 1 |
| Lê, AD | 1 |
| Harding, S | 1 |
| Juzytsch, W | 1 |
| Fletcher, PJ | 1 |
| Shaham, Y | 1 |
| Hurt, RD | 1 |
| Kaplan, GB | 1 |
| McRoberts, RL | 1 |
| Smokler, HJ | 1 |
| Cornelius, JR | 8 |
| Clark, DB | 2 |
| Bukstein, OG | 2 |
| Kelly, TM | 1 |
| Salloum, IM | 8 |
| Wood, DS | 1 |
| Birmaher, B | 1 |
| Brown, SA | 1 |
| Mistler, LA | 1 |
| Brunette, MF | 1 |
| Rosenberg, SD | 1 |
| Vidaver, RM | 1 |
| Luckoor, R | 1 |
| Iber, M | 1 |
| Carlson, JA | 1 |
| Mazza, J | 1 |
| Kircher, K | 1 |
| Tran, TA | 1 |
| Zalewska-Kaszubska, J | 1 |
| Górska, D | 1 |
| Dyr, W | 1 |
| Czarnecka, E | 1 |
| Cornelius, MD | 4 |
| Perel, JM | 5 |
| Ehler, JG | 4 |
| Jarrett, PJ | 3 |
| Levin, RL | 1 |
| Black, A | 3 |
| Mann, JJ | 2 |
| Polles, AG | 1 |
| Smith, PO | 1 |
| Finley, PR | 1 |
| Balon, R | 1 |
| Naranjo, CA | 3 |
| Poulos, CX | 1 |
| Bremner, KE | 1 |
| Lanctot, KL | 1 |
| Kranzler, HR | 3 |
| Burleson, JA | 2 |
| Korner, P | 1 |
| Del Boca, FK | 2 |
| Bohn, MJ | 1 |
| Brown, J | 3 |
| Liebowitz, N | 1 |
| Slywka, S | 1 |
| Hart, LL | 1 |
| Thase, ME | 5 |
| Meert, TF | 1 |
| Joseph, AP | 1 |
| Farmer, A | 1 |
| Kabel, DI | 1 |
| Petty, F | 1 |
| Janiri, L | 1 |
| Gobbi, G | 1 |
| Mannelli, P | 1 |
| Pozzi, G | 1 |
| Serretti, A | 1 |
| Tempesta, E | 1 |
| Korner, PF | 1 |
| Babor, TF | 1 |
| Khouzam, HR | 1 |
| Kissmeyer, P | 1 |
| Gardell, LR | 1 |
| Whalen, CA | 1 |
| Chattophadyay, S | 1 |
| Cavallaro, CA | 1 |
| Hubbell, CL | 1 |
| Reid, LD | 1 |
| Zhou, FC | 1 |
| McKinzie, DL | 1 |
| Patel, TD | 1 |
| Lumeng, L | 2 |
| Li, TK | 2 |
| Haskett, RF | 1 |
| Daley, DC | 1 |
| Jones-Barlock, A | 1 |
| Upsher, C | 1 |
| Anton, RF | 1 |
| Perkins, KA | 1 |
| Moss, HB | 1 |
| Maurel, S | 2 |
| De Vry, J | 2 |
| Schreiber, R | 2 |
| Farren, CK | 1 |
| O'Malley, SS | 1 |
| de Beun, R | 1 |
| Jentzsch, KR | 1 |
| Knoke, DM | 1 |
| Pettinati, HM | 1 |
| Gorelick, DA | 1 |
| Paredes, A | 1 |
| Rezvani, AH | 2 |
| Overstreet, DH | 2 |
| Janowsky, DS | 2 |
| Kadlec, KE | 1 |
| Sanhueza, P | 1 |
| Woodley-Remus, D | 1 |
| Sellers, EM | 1 |
| McBride, WJ | 1 |
| Murphy, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Fluoxetine on Measures of Domestic Violence[NCT00011765] | Phase 2 | 104 participants (Actual) | Interventional | 2001-02-22 | Completed | ||
| 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652] | 133 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -0.44 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.68 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.59 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in BDIS (Ondansetron) | Change in BDIS (Placebo) | |
| Prevention of Physical Dependence | -0.6 | 0.2 |
"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 3.6 | 3.6 |
"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Physical Dependence | 4.5 | 4.2 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in VAS Score (Ondansetron) | Change in VAS Score (Placebo) | |
| Prevention of Physical Dependence | -2.9 | -2.8 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in RMDI (Ondansetron) | Change in RMDI (Placebo) | |
| Prevention of Physical Dependence | -4.6 | -2.0 |
The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 12.5 | 12.2 |
The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Physical Dependence | 16.4 | 12.0 |
Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS Score (Ondansetron) | Change in POMS Score (Placebo) | |
| Prevention of Opioid Withdrawal | 29.3 | 28.3 |
(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS (Ondansetron) | Change in POMS (Placebo) | |
| Prevention of Physical Dependence | 36.1 | 29.2 |
7 reviews available for fluoxetine and Alcoholism
| Article | Year |
|---|---|
Pharmacotherapy for alcoholic smokers.
Topics: Alcoholism; Animals; Fluoxetine; Humans; Nicotine; Smoking | 2002 |
Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review.
Topics: Adolescent; Alcohol Drinking; Alcoholism; Antidepressive Agents, Second-Generation; Combined Modalit | 2005 |
Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions.
Topics: 1-Naphthylamine; Alcoholism; Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Dep | 1994 |
Fluoxetine in alcoholism.
Topics: Alcoholism; Animals; Double-Blind Method; Fluoxetine; Humans; Male; Prospective Studies; Rats | 1993 |
Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions.
Topics: Alcoholism; Bromocriptine; Dopamine Agonists; Female; Fluoxetine; Humans; Male; Models, Psychologica | 1996 |
The role of selective serotonin reuptake inhibitors in reducing alcohol consumption.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Addictive; Behavior, Animal; Citalopram; Clinical T | 2001 |
The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes.
Topics: Alcoholism; Clinical Trials as Topic; Comorbidity; Depressive Disorder; Drug Administration Schedule | 2001 |
17 trials available for fluoxetine and Alcoholism
| Article | Year |
|---|---|
[Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study].
Topics: Alcoholism; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective | 2021 |
Fluoxetine treatment of alcoholic perpetrators of domestic violence: a 12-week, double-blind, randomized, placebo-controlled intervention study.
Topics: Aggression; Alcoholics Anonymous; Alcoholism; Anger; Cognitive Behavioral Therapy; Combined Modality | 2011 |
Moderators of fluoxetine treatment response for children and adolescents with comorbid depression and substance use disorders.
Topics: Adolescent; Alcoholism; Antidepressive Agents, Second-Generation; Child; Chronic Disease; Depressive | 2012 |
Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics.
Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Depression; Double-Blind Method; Female; Fluoxetine | 1995 |
Fluoxetine attenuates alcohol intake and desire to drink.
Topics: Adult; Alcohol Drinking; Alcoholism; Appetite; Dose-Response Relationship, Drug; Double-Blind Method | 1994 |
Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics.
Topics: Adult; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Comorbidity; Depressive Disorder; Dr | 1995 |
Fluoxetine trial in suicidal depressed alcoholics.
Topics: Adult; Alcoholism; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; Psychiatric S | 1993 |
A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment.
Topics: Adult; Aftercare; Alcoholism; Combined Modality Therapy; Double-Blind Method; Fluoxetine; Humans; Ma | 1996 |
Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics.
Topics: Adult; Alcoholism; Double-Blind Method; Ethanol; Female; Fluoxetine; Humans; Italy; Male; Middle Age | 1996 |
Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer.
Topics: Alcoholism; Anti-Anxiety Agents; Buspirone; Dose-Response Relationship, Drug; Double-Blind Method; F | 1996 |
Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Comorbidity; Depressive Disorder; | 1996 |
Double-blind fluoxetine in depressed alcoholic smokers.
Topics: Adult; Alcoholism; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Metho | 1997 |
Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Comorbidity; Depressive Disorder; Diagnosis, Dual (Psychiatry); | 1997 |
Fluoxetine versus placebo in depressed alcoholic cocaine abusers.
Topics: Adult; Alcoholism; Antidepressive Agents, Second-Generation; Cocaine; Depressive Disorder; Double-Bl | 1998 |
Fluoxetine versus placebo to decrease the smoking of depressed alcoholic patients.
Topics: Adult; Alcoholism; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middl | 1999 |
Effect of fluoxetine on alcohol consumption in male alcoholics.
Topics: Adult; Alcohol Drinking; Alcoholism; Fluoxetine; Hospitalization; Humans; Male; Middle Aged; Single- | 1992 |
Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers.
Topics: Adult; Alcohol Drinking; Alcoholism; Analysis of Variance; Appetite; Body Weight; Drinking Behavior; | 1990 |
27 other studies available for fluoxetine and Alcoholism
| Article | Year |
|---|---|
Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders.
Topics: Adult; Alcoholism; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Fluoxetine; Humans; Middle A | 2021 |
Bupropion, a possible antidepressant without negative effects on alcohol relapse.
Topics: Alcohol Drinking; Alcoholism; Animals; Antidepressive Agents, Second-Generation; Bupropion; Dopamine | 2019 |
Cessation of fluoxetine treatment increases alcohol seeking during relapse and dysregulates endocannabinoid and glutamatergic signaling in the central amygdala.
Topics: Alcoholism; Animals; Central Amygdaloid Nucleus; Disease Models, Animal; Drug-Seeking Behavior; Endo | 2020 |
Evaluation of the antidepressant, anxiolytic and memory-improving efficacy of aripiprazole and fluoxetine in ethanol-treated rats.
Topics: Alcoholism; Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; | 2014 |
Evaluation of antidepressant and memory-improving efficacy of aripiprazole and fluoxetine in alcohol-preferring rats.
Topics: Alcoholism; Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Fluoxetine; Male; Pi | 2014 |
[Buccolingual dyskinesia with justified hallucinations].
Topics: Alcoholism; Benzodiazepines; Clonazepam; Depressive Disorder; Dibenzothiazepines; Disulfiram; Female | 2014 |
Fluoxetine might alleviate brain damage and hypercortisolemia related to chronic alcohol in rats.
Topics: Alcoholism; Animals; Cerebral Cortex; Fluoxetine; Hydrocortisone; Male; Neurons; Rats; Rats, Wistar; | 2010 |
Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats.
Topics: Alcoholism; Analysis of Variance; Animals; Antidepressive Agents; Central Nervous System Depressants | 2011 |
The role of corticotropin-releasing factor in the median raphe nucleus in relapse to alcohol.
Topics: Alcoholism; Animals; Behavior, Animal; Choice Behavior; Corticotropin-Releasing Hormone; Disease Mod | 2002 |
Baclofen as adjunctive treatment for a patient with cocaine dependence and schizoaffective disorder.
Topics: Alcoholism; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Baclofen; Bipolar Disord | 2004 |
Fluoxetine in adolescents with comorbid major depression and an alcohol use disorder: a 3-year follow-up study.
Topics: Adolescent; Alcoholism; Combined Modality Therapy; Comorbidity; Depression; Diagnosis, Dual (Psychia | 2005 |
Case report of 3 patients with severe mental illness and chronic hepatitis C virus infection treated with interferon-alpha.
Topics: Adult; Alcoholics Anonymous; Alcoholism; Anticonvulsants; Antidepressive Agents, Second-Generation; | 2006 |
Otophyma: a case report and review of the literature of lymphedema (elephantiasis) of the ear.
Topics: Adrenal Cortex Hormones; Alcoholism; Anti-Infective Agents; Anti-Inflammatory Agents; Antidepressive | 2008 |
Lack of changes in beta-endorphin plasma levels after repeated treatment with fluoxetine: possible implications for the treatment of alcoholism--a pilot study.
Topics: Alcoholism; Animals; Antidepressive Agents, Second-Generation; beta-Endorphin; Female; Fluoxetine; H | 2008 |
Treatment of coexisting substance dependence and posttramatic stress disorder.
Topics: Adult; Alcoholism; Behavior Therapy; Combined Modality Therapy; Comorbidity; Fluoxetine; Humans; Ill | 1995 |
Fluoxetine for cocaine dependence in methadone maintenance.
Topics: Alcoholism; Cocaine; Dopamine Uptake Inhibitors; Drug Synergism; Fluoxetine; Heroin Dependence; Huma | 1994 |
Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Chlordiazepoxide; Citalopram; Dose-Response Relati | 1993 |
An unusual case of central pontine myelinolysis.
Topics: Alcoholism; Antidepressive Agents; Brain Diseases; Depressive Disorder; Fluoxetine; Humans; Hyponatr | 1995 |
Antidepressant treatment, posttraumatic stress disorder, survivor guilt, and spiritual awakening.
Topics: Alcoholism; Antidepressive Agents, Second-Generation; Awareness; Combat Disorders; Combined Modality | 1997 |
Combination of naltrexone and fluoxetine on rats' propensity to take alcoholic beverage.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Sy | 1997 |
Additive reduction of alcohol drinking by 5-HT1A antagonist WAY 100635 and serotonin uptake blocker fluoxetine in alcohol-preferring P rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Synergism; Female; Flu | 1998 |
Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Citalopram; Disease Models, Animal; Eating; Ethanol; Female; | 1999 |
Occurrence and management of depression in the context of naltrexone treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Comorbidity; Depressive Disorder; Dia | 1999 |
Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism.
Topics: Alcoholism; Animals; Antidepressive Agents; Depression; Drug Evaluation, Preclinical; Female; Fluoxe | 1999 |
Drug-induced reductions in ethanol intake in alcohol preferring and Fawn-Hooded rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Drinking Behavior; Ethanol; Feeding Behavior; Fluo | 1991 |
Genetic serotonin deficiency and alcohol preference in the fawn hooded rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Brain; Fluoxetine; Rats; Rats, Inbred Strains; Receptors, Ser | 1990 |
Effects of Ro 15-4513, fluoxetine and desipramine on the intake of ethanol, water and food by the alcohol-preferring (P) and -nonpreferring (NP) lines of rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Azides; Benzodiazepines; Desipramine; Drinking Behavior; Feed | 1988 |